GSK plc Sponsored ADR (GSK)
GSK Q3 Earnings Top, Stock Down on Lowered '24 View for Vaccine Sales
GSK's Q3 earnings beat estimates but sales miss the same. The company also lowers its outlook for vaccine sales for the rest of the year due to weak U.S. demand.
GSK plc (GSK) Q3 2024 Earnings Call Transcript
GSK plc (NYSE:GSK ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Emma Walmsley - CEO Luke Miels - Chief Commercial Officer Deborah Waterhouse - CEO, ViiV Healthcare Julie Brown - CFO Jeff McLaughlin - IR Tony Wood - Chief Scientific Officer Conference Call Participants James Gordon - JPMorgan Kerry Holford - Berenberg Jo Walton - UBS Simon Baker - Redburn Atlantic Graham Parry - Bank of America Emmanuel Papadakis - Deutsche Bank Richard Parkes - BNP Paribas Peter Welford - Jefferies Operator Hello, everyone. Welcome to today's call and webcast.
GSK (GSK) Q3 Earnings Surpass Estimates
GSK (GSK) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.26 per share a year ago.
GSK: Earnings Confirm It's On Track To Meet Guidance
GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. For 9m 2024, the company's turnover growth at 9% is at the upper end of the guidance range and core EPS growth of 14% exceeds it. While the numbers slumped in Q3 2024, this was expected, especially as reported earnings absorbed Zantac related payouts. They are unlikely to impact full year figures, however.
GSK Stock Crumbles As Vaccine Sales Plummet And Miss Expectations
GSK stock crumbled on Wednesday after vaccine sales tumbled, leading to a third-quarter miss. Revenue from RSV shot Arexvy skidded.
GSK's Q3 Earnings Hit By Lower Than Expected Vaccine Sales, Cautions Lower Revenue For 2024
Wednesday, GSK Plc GSK reported third-quarter sales of $10.42 billion (8.01 billion Sterling Pounds), down 2% year-over-year and up 2% on constant currency. The analysts estimated sales of $10.78 billion.
GSK Stock Drops as UK Firm Posts Underwhelming Results
GSK's (GSK) shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lower-than-estimated quarterly sales and lowered its projection for vaccine sales.
GSK cuts vaccine sales target on reduced demand
U.K. drugmaker GSK on Wednesday cut its vaccine sales guidance for the year after what it called lower-than-expected demand.
GSK falls 3% as vaccines disappoint (again)
Dedicated followers of GSK PLC (LSE:GSK, NYSE:GSK) will have been aware of analysts' growing unease around the performance of its vaccine franchise - backed up by prescription data. Third-quarter results effectively confirmed the numbers crunchers' worst fears (and some) as sales of RSV jab Arexvy and Shingles treatment Shingrix undershot forecasts as they came in at £188 million and £739 million respectively.
GSK lowers 2024 vaccine sales forecast
GSK lowered its 2024 vaccine sales forecast for the second time this year on Wednesday, hit by weak demand for its respiratory syncytial virus (RSV) and shingles vaccines.
GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy'
GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company's diversified portfolio includes vaccines, specialty medicines, and general medicines, with significant contributions from HIV and oncology treatments. Despite legal and regulatory challenges, GSK's strategic partnerships and international expansion, particularly in China, enhance its growth potential.
GSK looking to moveon from Zantac in forthcoming update
GSK PLC (LSE:GSK, NYSE:GSK) share price bump on settlement of most of its Zantac litigation claims has reversed recently on concerns about two key products, Arexvy and Shingrix, in the important US market. Those three elements will dominate next week's trading update with confirmation that the end of the Zantac issue is in sight one thing investors would like to hear.
